Amity Bio Co., Ltd. (CEO: Ki-Hwan Cho), a pharmaceutical development venture company, announced on the 4th that it received a commendation from the Chairman of the Health and Welfare Committee at the '2025 5th Republic of Korea Contribution Awards' on August 30th.
At an awards ceremony held in the conference room of the National Assembly Members' Hall in Yeouido, Seoul, CEO Cho Ki-hwan received a commendation for his contributions to improving public health. The "Republic of Korea Contribution Awards" recognizes and honors individuals who have contributed to social development across seven fields: education, culture, sports, legislative affairs, administration, volunteer work, and the environment. The awards ceremony, co-hosted by the Korea Environment Sports Youth Federation and Democratic Party of Korea lawmaker Kim Moon-soo, is organized by the Korea Contribution Awards Organizing Committee.
EmetiBio, an innovative growth-type venture company, was highly evaluated for its contribution to improving medical services and promoting public health by supplying specialized pharmaceuticals that improve patient safety and clinical field utilization through collaboration with domestic pharmaceutical and bio companies.
CEO Cho Ki-hwan established Medtop, a pharmaceutical distribution company, in 2019 after working at the Marketing Headquarters of Chungwoo Pharmaceutical and the Business Strategy Headquarters of Astellas Korea. The company changed its name to Emetibio Co., Ltd. in 2024. In 2023, the company launched its own drug, "Prozea," generating sales of over 10 billion won. Starting with the launch of a new antiemetic, "Lamosta," in 2025, the company aims to expand its product lineup to around 30 products and increase sales to over 30 billion won by 2028.
You must be logged in to post a comment.